What type of follow-up is needed for this patient during treatment and afterward?
Historically patients with metastatic prostate cancer would be followed after starting a treatment like leuprolide acetate every three months. As long as they were responding and their PSAs would go down, they may see the urologist or the oncologist while they get their injections, and that type of intensity was really because there was nothing else you could do except the androgen deprivation therapy.
In the setting of docetaxel for hormone-sensitive metastatic prostate cancer, we’re seeing these patients every three weeks obviously, because we’re giving them chemotherapy during that initial period in addition to androgen deprivation therapy. So we’re seeing them much more intensively.
CASE: Metastatic Prostate Cancer (Part 2)
Mathew J is a 61 year old African American male who presented to his primary care physician with lower urinary tract symptoms, including sporadic hematuria. He complains of abdominal pain and low back pain starting four months ago and increasing in frequency. Prior medical history includes non-insulin dependent diabetes mellitus, well-controlled on metformin since 2006. The patient was referred to urology for further evaluation. ng/ml.
During his most recent follow-up exam, the patient complained of intermittent back pain and increasing fatigue.
Apalutamide Outperforms Enzalutamide in mCSPC Survival
November 8th 2024In an interview with Targeted Oncology, Neal Shore, MD, FACS, discussed the background, findings, and implications of a real-world study of enzalutamide and apalutamide in patients with metastatic castration-sensitive prostate cancer.
Read More